Attana and partners receives €1.1 million from Knowledge Foundation

Report this content

Stockholm June 27 th, 2017. Attana AB, AstraZeneca, Akzo Nobel Pulp and Performance Chemicals AB and Ridgeview Instruments AB together with Karlstad University, Linnaeus University and Örebro University has been granted €1.1 million from The Swedish Knowledge Foundation (KK-stiftelsen). The grant is aimed for development of methods for characterization and quality control of purification of biopharmaceuticals.

The project aims at developing flexible processes for quality control of biopharmaceuticals production. The ambition is to allow continuous improvements of the analytical methods used for quality control without the need for costly and time consuming regulatory approval every time an improvement is implemented.

"Currently pharmaceutical companies need to follow the regulatory approved method in detail. The consequence of that, is that when improvements are made they are forced to use the old approved methods or submit expensive and time-consuming requests for changes to the regulatory authorities" says Prof. Torgny Fornstedt at Karlstad University.

"Every time we have changed a regulatory approved analytical method for quality control, we have had to pay several hundred thousand of euros in fees to regulatory authorities around the world and it can take up to two years to obtain the approval’" says Dr Anders Karlsson Head of Quality Control at AstraZeneca R&D Gothenburg.

"This project is state of the art both scientifically and in volume. It is a strategically important project for the collaboration between industry and universities in Sweden and will include a significant amount of knowledge transfer between the contributing partners’" says Mats Waltré, program manager at KK-stiftelsen.

"Attana´s 3rdgeneration biosensor has a perfect match for this kind of characterization, where our detail interaction profiling can detect the influence of small amounts of contamination on the interaction performances" says Dr. Teodor Aastrup, CEO and co-founder of Attana.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
tel: + 46 70 15676765

Our team provide customers with biologically relevant information to enhance their success rate and efficiency of research and development process. Our world leading cell interaction technology have been validated by academic institutions, biotech companies and big-pharma across the world. With a strong focus on characterizing molecular interactions exactly as they occur in the human body, Attana is committed to offer tools and services with the goal of enhancing success rates and efficiencies in the complex process of developing pharmaceuticals. Attana’s 3 rd generations biosensors are today used to determine specificity, kinetics and affinity, among other binding characteristics of biomolecules and macrostructures of varying species such as cells, antibodies, proteins, viruses and bacteria.

We are located in Stockholm and have a strong footprint in Europe and Asia.


Documents & Links